drugset / Trial / NCT01809847

Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation

NCT01809847

NaSingle-groupOpen-labelTreatment

Summary

To study the safety and efficacy of anti-CD20 blockade with ofatumumab in the context of allogeneic HCT in CLL

Timeline

Start
2013-03
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofatumumab Monoclonal antibody 1000 mg